Tocagen believes the immune system can be safely activated to fight the patient’s cancer. Driven by this vision, we are developing first-in-class, broadly applicable, product candidates designed to activate a patient’s immune system against their own cancer from within.
Tocagen has developed a new product candidate for cancer, Toca 521. This investigational compound targets PD-L1 from within, potentially overcoming limitations of available checkpoint inhibitors and improving patient outcomes.
Tocagen is advancing a broadly applicable, cancer-selective gene therapy platform that is designed to deliver therapeutic genes into the DNA of cancer cells and activate a patient’s immune system against their own cancer from within.
Tocagen is committed to fighting cancer. We have multiple clinical trials ongoing with our lead cancer-selective gene therapy product candidate, Toca 511 & Toca FC.
Tocagen is a clinical-stage, cancer-selective gene therapy company focused on developing first-in-class, broadly-applicable product candidates designed to activate a patient’s immune system against their own cancer from within.
Tocagen Reports Third Quarter 2018 Financial and Business Results
Interested in following our progress? Subscribe below.